Avidity Partners Management LP Verve Therapeutics, Inc. Transaction History

Avidity Partners Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$11.42 - $20.82 $6.78 Million - $12.4 Million	-593,266 Reduced 67.52%	285,334 $3.78 Million
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $6.31 Million - $9.41 Million	-473,100 Reduced 35.0%	878,600 $16.5 Million
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $3.05 Million - $5.12 Million	-213,300 Reduced 13.63%	1,351,700 $19.5 Million
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $9.32 Million - $21.3 Million	522,294 Added 50.09%	1,565,000 $30.3 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $16.3 Million - $43.3 Million	1,042,706 New	1,042,706 $35.8 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $317M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.